(NASDAQ: TCRX) Tscan Therapeutics's forecast annual revenue growth rate of 152.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Tscan Therapeutics's revenue in 2025 is $6,961,000.On average, 3 Wall Street analysts forecast TCRX's revenue for 2025 to be $548,923,336, with the lowest TCRX revenue forecast at $246,853,770, and the highest TCRX revenue forecast at $851,219,895. On average, 3 Wall Street analysts forecast TCRX's revenue for 2026 to be $730,914,150, with the lowest TCRX revenue forecast at $141,869,983, and the highest TCRX revenue forecast at $1,157,091,577.
In 2027, TCRX is forecast to generate $8,032,054,181 in revenue, with the lowest revenue forecast at $4,065,993,698 and the highest revenue forecast at $11,998,114,664.